Clinical development programs employing monoclonal antibodies specific for either folate receptor alpha in certain cancers of epithelial origin, including EOC, and folate receptor beta in inflammatory disorders such as arthritis, are underway. The gene discussed is FOLR2; the disease is arthritic joint disease.